ATE275979T1 - Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten - Google Patents

Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten

Info

Publication number
ATE275979T1
ATE275979T1 AT01948294T AT01948294T ATE275979T1 AT E275979 T1 ATE275979 T1 AT E275979T1 AT 01948294 T AT01948294 T AT 01948294T AT 01948294 T AT01948294 T AT 01948294T AT E275979 T1 ATE275979 T1 AT E275979T1
Authority
AT
Austria
Prior art keywords
pegylation
antitumor activity
reduces toxicity
immune conjugates
present
Prior art date
Application number
AT01948294T
Other languages
English (en)
Inventor
Ira H Pastan
Yasuo Tsutsumi
Masanori Onda
Satoshi Nagata
Byungkook Lee
Original Assignee
Us Gov Health & Human Serv
Kreitman Robert J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Kreitman Robert J filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE275979T1 publication Critical patent/ATE275979T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01948294T 2000-06-09 2001-06-08 Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten ATE275979T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21133100P 2000-06-09 2000-06-09
US21380400P 2000-06-22 2000-06-22
PCT/US2001/018503 WO2001095942A2 (en) 2000-06-09 2001-06-08 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates

Publications (1)

Publication Number Publication Date
ATE275979T1 true ATE275979T1 (de) 2004-10-15

Family

ID=26906053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948294T ATE275979T1 (de) 2000-06-09 2001-06-08 Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten

Country Status (9)

Country Link
EP (1) EP1351709B8 (de)
JP (1) JP2004503512A (de)
AT (1) ATE275979T1 (de)
AU (2) AU6976201A (de)
CA (1) CA2411967A1 (de)
DE (1) DE60105647T2 (de)
DK (1) DK1351709T3 (de)
ES (1) ES2228903T3 (de)
WO (1) WO2001095942A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
PL1639011T3 (pl) * 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
AU2005263555B2 (en) * 2004-07-16 2011-01-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
EP2860253B1 (de) 2006-03-01 2018-08-01 Aduro Biotech, Inc. Manipulierte Listerien und Anwendungsverfahren dafür
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
CA2695830A1 (en) * 2007-08-08 2009-02-12 Novozymes Biopharma Dk A/S Transferrin variants and conjugates
WO2009021754A2 (en) * 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
US7800951B2 (en) 2007-08-20 2010-09-21 Marvell World Trade Ltd. Threshold voltage digitizer for array of programmable threshold transistors
KR101952460B1 (ko) 2010-12-03 2019-02-27 아다메드 파르마 에스.에이. 항암 융합 단백질
CN104620093B (zh) * 2012-08-23 2018-04-20 干细胞技术公司 用于快速可逆生物分子标记的组合物和方法
WO2022178751A1 (en) * 2021-02-25 2022-09-01 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates comprising effector molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1783222T3 (da) * 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet

Also Published As

Publication number Publication date
ES2228903T3 (es) 2005-04-16
EP1351709B1 (de) 2004-09-15
DK1351709T3 (da) 2005-01-31
WO2001095942A2 (en) 2001-12-20
AU2001269762C1 (en) 2005-12-22
AU2001269762B2 (en) 2005-06-23
DE60105647T2 (de) 2005-09-22
AU6976201A (en) 2001-12-24
DE60105647D1 (de) 2004-10-21
WO2001095942A3 (en) 2003-07-31
CA2411967A1 (en) 2001-12-20
JP2004503512A (ja) 2004-02-05
EP1351709B8 (de) 2004-12-22
EP1351709A2 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
IL169045A (en) Immunoconjugates
ATE275979T1 (de) Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten
CL2023003304A1 (es) Derivados de exatecán y sus conjugados anticuerpo-fármaco
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
EP1017397A4 (de) Photo-empfindlichkeit-erhöhende conjugate zur targeting von pathogene
WO2005112919A8 (en) Self-immolative linkers and drug conjugates
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
PL374523A1 (en) Calicheamicin derivative-carrier conjugates
BR122018071968B8 (pt) conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
TW200510454A (en) Conjugates comprising human IL-18 and substitution mutants thereof
IL189461A (en) A process for making factor pairs binds @ cells and causes @ toxic @ cells
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
WO2007038658A3 (en) Antibody-drug conjugates and methods of use
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
CY1106886T1 (el) Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
NZ762865A (en) Psma-targeting amanitin conjugates
WO2018124512A3 (ko) 압타머-약물 콘쥬게이트 및 그 용도
AU2002215904A1 (en) Compounds with a branched linker
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
WO2005041881A3 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2002049672A3 (en) Conjugates of antibodies and anticancer drugs
HK1067492A1 (en) Method of making a homogenous doxorubicin-transferrin conjugate
MX2022015147A (es) Conjugados de anticuerpos biespecíficos-fármacos dirigidos al receptor del factor de crecimiento epidérmico (egfr) y glicoproteína de transmembrana de tipo 1 (muc1) y usos de los mismos.
MX2021003295A (es) Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1351709

Country of ref document: EP

REN Ceased due to non-payment of the annual fee